BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) of $5.29 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-22.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease · last filed 2012-02-22
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $3.58M, a 66.14% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $7.91M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was -$372.00K, a 106.02% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-03-31 was -$5.84M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2011 was $5.29M, a 3245.57% increase from fiscal 2010.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2010 was $158.00K.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2009 was -$477.00K.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2011-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $11.49M derived: sum of 2 quarters · filed 2012-02-22 | $11.12M derived: sum of 3 quarters · filed 2012-02-22 | $5.29M 10-K · filed 2012-02-22 |
| 2011-09-30 | $7.91M 10-Q · filed 2011-10-31 | $7.54M derived: sum of 2 quarters · filed 2011-10-31 | $1.70M 10-Q · filed 2011-10-31 | $3.86M derived: sum of 4 quarters · filed 2012-02-22 |
| 2011-06-30 | -$372.00K 10-Q · filed 2011-08-01 | -$6.21M 10-Q · filed 2011-08-01 | -$4.05M derived: sum of 3 quarters · filed 2012-02-22 | -$16.29M derived: sum of 4 quarters · filed 2012-02-22 |
| 2011-03-31 | -$5.84M derived: 10-K 12 month − 3 quarters · filed 2012-02-22 | -$3.68M derived: sum of 2 quarters · filed 2012-02-22 | -$15.92M derived: sum of 3 quarters · filed 2012-02-22 | -$9.74M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$10.08M derived: sum of 2 quarters · filed 2012-02-22 | -$3.90M derived: sum of 3 quarters · filed 2012-02-22 | $158.00K 10-K · filed 2012-02-22 |
| 2010-09-30 | -$12.24M 10-Q · filed 2011-10-31 | -$6.06M derived: sum of 2 quarters · filed 2011-10-31 | -$2.00M 10-Q · filed 2011-10-31 | |
| 2010-06-30 | $6.18M 10-Q · filed 2011-08-01 | $10.24M 10-Q · filed 2011-08-01 | ||
| 2009-12-31 | -$477.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |